Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).

Adding MRI to annual mammography screening improves early breast cancer detection in women with familial risk or BRCA1/2 mutation, but breast cancer specific metastasis free survival (MFS) remains unknown. We compared MFS of patients from the largest prospective MRI Screening Study (MRISC) with 1:1 matched controls. Controls, unscreened if<50 years, and screened with biennial mammography if 50 years, were matched on risk category (BRCA1, BRCA2, familial risk), year and age of diagnosis. Of 2,308 MRISC participants, breast cancer was detected in 93 (97 breast cancers), who received MRI <2 years before breast cancer diagnosis; 33 BRCA1 mutation carriers, 18 BRCA2 mutation carriers, and 42 with familial risk. MRISC patients had smaller (87% vs. 52%

Keywords:

• Mastectomy
• Gastroenterology
• Breast cancer
• Cancer research
• Mammography
• Annual Screening
• Hormonal therapy
• Gynecology
• Population
• Familial predisposition
• Metastasis
• Medicine
• Internal medicine
• Case-control study
• Prospective cohort study

• Correction
• Source
• Cite
• Save
• Machine Reading By IdeaReader